Acrivon Therapeutics Inc
acrivon.comAcrivon Therapeutics Inc (NASDAQ: ACRV) is a clinical-stage biopharmaceutical company that develops oncology drugs paired with proprietary predictive biomarker tests designed to identify which patients are most likely to respond to treatment. The company generates no product revenue as of the 10-K filed 2026-03-19, funding operations through equity offerings, debt financings, and potential collaboration arrangements. Acrivon's lead asset is ACR-368, a CHK1/CHK2 inhibitor being evaluated in Phase 2b clinical trials across multiple tumor types, including endometrial cancer, under the ACR-368-201 master protocol trial. The companion OncoSignature test, built on Acrivon's AP3 proteomics platform, stratifies patients prospectively by predicted sensitivity to ACR-368. The company also has ACR-2316 in development. As of December 31, 2025, Acrivon held approximately $153.2 million in federal net operating loss carryforwards, reflecting its pre-revenue, development-stage status. Principal offices are in Watertown, Massachusetts, with additional laboratory and office space in Lund, Sweden.
Products & Services
ACR-368: a CHK1/CHK2 inhibitor in Phase 2b clinical trials (ACR-368-201 master protocol) across multiple solid tumor types including endometrial cancer. ACR-368 OncoSignature: a protein-based tumor biopsy test built on the AP3 proteomics platform, used to prospectively identify patients predicted to respond to ACR-368. ACR-2316: a second drug candidate in development. AP3 platform: the underlying proteomics technology used for biomarker and indication discovery.
Revenue Model
No product revenue as of the 10-K filed 2026-03-19. Operations are financed through equity offerings, debt financings, and potential collaborations. The company has not yet generated substantial drug revenues.
Customers & Markets
End market is oncology, specifically patients with solid tumors including endometrial cancer. Clinical trial sites are located across the United States. No commercial customers as of the filing date.
Geographic Exposure
Primary operations in Watertown, Massachusetts (13,711 square feet, lease expiring 2028). Secondary operations in Lund, Sweden (529 square meters plus additional adjacent space leased from September 2024, initial three-year term). Clinical trial sites in the United States.
Financial Snapshot
Loading...
